Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,634 matching trials from the live ClinicalTrials.gov search.
Filters: Los Angeles, California Clear all
Active, not recruiting Phase 3 Interventional

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Bomedemstat, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Glendale, Arizona • Glendale, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325442
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) sustained release tablets, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Impact of a Brief Motivational Interview on Drinking Behaviors of At Risk Drinkers Screened in the Emergency Room

NCT00183183
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Screening and Brief Intervention
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
1,137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Nov 3, 2026, 9:23 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

NCT00688246
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
biologic sample preservation procedure, dual x-ray absorptometry
Other · Procedure
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
13
States / cities
Torrance, California • Washington D.C., District of Columbia • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Nov 3, 2026, 9:23 AM EST
Completed Not applicable Interventional

Better Effectiveness After Transition - Heart Failure

NCT01360203
View directory record Official record
Conditions
Heart Failure
Interventions
Structured Telephone / Remote Outpatient Monitoring
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
1,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Davis, California • Irvine, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Nov 3, 2026, 9:23 AM EST
Terminated Phase 4 Interventional Results available

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT04506086
View directory record Official record
Conditions
B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Nov 3, 2026, 9:23 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986482, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Irvine, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02604810
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IGIV-C 10%, IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Nov 3, 2026, 9:23 AM EST
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
Cytarabine, Idarubicin Hydrochloride, Navtemadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed No phase listed Observational

Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury

NCT00605527
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Days to 18 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
Fresno, California • Los Angeles, California • Oakland, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Nov 3, 2026, 9:23 AM EST
Recruiting Phase 1Phase 2 Interventional

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

NCT05634369
View directory record Official record
Conditions
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
Interventions
GEM/DOX + TGFBi expanded NK cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
South Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

NCT07136623
View directory record Official record
Conditions
Pulmnary Hypertension
Interventions
Eko CORE 500 phonocardiogram (PCG) recording, Eko CORE 500 three-lead electrocardiogram (ECG) recording
Diagnostic Test
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

NCT03070223
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pitavastatin, Placebos
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Nov 3, 2026, 9:23 AM EST
Completed Not applicable Interventional Results available

Effort of Breathing Guided Ventilator Protocol

NCT02989246
View directory record Official record
Conditions
Ventilators, Mechanical, Work of Breathing
Interventions
Ventilator protocol, Esophageal Catheter
Other · Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
37 Weeks to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 3, 2026, 9:23 AM EST
Not listed No phase listed Observational

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

NCT06154070
View directory record Official record
Conditions
Migraine Disorders
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Nov 3, 2026, 9:23 AM EST
Terminated Phase 2 Interventional Results available

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT01814813
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions
HSPPC-96, bevacizumab
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
417
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

NCT00025259
View directory record Official record
Conditions
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions
Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
1,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
153
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Nov 3, 2026, 9:23 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Study of Recently HIV Infected Men and Transmission Behaviors

NCT01201083
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Nov 3, 2026, 9:23 AM EST
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Nov 3, 2026, 9:23 AM EST
Not yet recruiting Phase 2 Interventional

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

NCT07812181
View directory record Official record
Conditions
Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Jonathan Santoro
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Recruiting Phase 2 Interventional

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

NCT00945009
View directory record Official record
Conditions
Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
Interventions
Dactinomycin, Doxorubicin Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery, Vincristine Sulfate
Biological · Drug · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
146
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 3, 2026, 9:23 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT00903175
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
everolimus, sunitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Nov 3, 2026, 9:23 AM EST